Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice

• Published in: Frontiers in pharmacology Vol. 12; p. 793349
• Main Authors: Kang, Won-Ho, Ryu, Hyo-Jeong, Kwak, Seongsung, Yun, Hwi-Yeol
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04-01-2022
• Subjects: botulinum neurotoxin; K-PD modeling; melanoma; pharmacodynamics; pharmacokinetics; Pharmacology; tumor growth inhibition; pharmacodynamics; pharmacokinetics; tumor growth inhibition; melanoma; K-PD modeling; botulinum neurotoxin; NONMEM
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.793349

In recent, Botulinum Neurotoxin A1 (BoNT/A1) has been suggested as a potential anticancer agent due to neuronal innervation in tumor cells. Although potential BoNT/A1's mechanism of action for the tumor suppression has been gradually revealed so far, there were no reports to figure out the exposure-response relationships because of the difficulty of its quantitation in the biological matrix. The main objectives of this study were to measure the anticancer effect of BoNT/A1 using a syngeneic mouse model transplanted with melanoma cells (B16-F10) and developed a kinetic-pharmacodynamic (K-PD) model for quantitative exposure-response evaluation. To overcome the lack of exposure information, the K-PD model was implemented by the virtual pharmacokinetic compartment link to the pharmacodynamic compartment of Simeoni's tumor growth inhibition model and evaluated using curve-fitting for the tumor growth-time profile after intratumoral injection of BoNT/A1. The final K-PD model was adequately explained for a pattern of tumor growth depending on represented exposure parameters and simulation studies were conducted to determine the optimal dose under various scenarios considering dose strength and frequency. The optimal dose range and regimen of ≥13.8 units kg
once a week or once every 3 days was predicted using the final model in B16-F10 syngeneic model and it was demonstrated with an extra
experiment. In conclusion, the K-PD model of BoNT/A1 was well developed to optimize the dosing regimen for evaluation of anticancer effect and this approach could be expandable to figure out quantitative interpretation of BoNT/A1's efficacy in various xenograft and/or syngeneic models.